More than meets the Kappa for Antibody Superantigen Protein L (PpL)

Wei-Li Ling^{1,2}, Joshua Yi Yeo¹, Yuen-Ling Ng², Anil Wipat³, Samuel Ken-En Gan^{*1,4}

¹ Antibody & Product Development Lab, Experimental Drug Development Centre – Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore

² Newcastle Research and Innovation Institute (NewRIIS), Singapore, Singapore

³ School of Computing, Newcastle University, Newcastle upon Tyne, UK

⁴ James Cook University, Singapore, Singapore

* Correspondence:

Samuel Ken-En Gan

samgan@apdskeg.com; samuel_gan@eddc.a-star.edu.sg

Keywords: Pertuzumab, Trastuzumab, IgG1, VH families, VK families, Protein L, Protein A, Protein G, Immunoglobulin Superantigen.

Abstract

Immunoglobulin superantigens play an important role in the affinity purification of antibodies and underlie the microbiota-immune axis at mucosal areas. Focussing on the *Staphylococcal* Protein A (SpA), *Streptococcal* Protein G (SpG), and the *Finagoldia* Protein L (PpL) that were previously thought to bind to only specific regions of human antibodies, a systematic and holistic analysis of the antibody regions using 63 antibody permutations involving six V κ and seven VH region IgG1 revealed showed novel PpL-antibody interactions. While SpA and SpG showed relatively consistent interactions with the antibodies, our findings showed PpL binding to certain VH-V κ 2, 5 and 6 interactions had contribution by other antibody regions. The findings of this have implications on PpL-based affinity antibody purifications and antibody design as well as provides novel insights to PpL-based microbiota-immune axis effects.

1 Introduction

B-cell superantigens bind antibodies or immunoglobulins (Ig) to hyperstimulate populations of B-cells independent of T-cells and have been widely used for antibody affinity purification (Deacy et al., 2021). Superantigens are predominantly produced by microorganisms as a defence

mechanism to escape from the host immune system (Spaulding et al., 2013). Notably there are three widely-used antibody superantigens also known as immunoglobulin binding proteins (IBP): Protein G (SpG) which binds the heavy chain constant region of the IgG subtypes (IgG1-4) and is produced by groups C and G of *Streptococcal* bacteria (Sjöbring et al., 1991); Protein A (SpA) produced by *Staphylococcus aureus* which also binds to the heavy chain constant region of IgG1, 2, and 4 and also the variable heavy (VH) 3 framework (VH3) (GROV et al., 1964; Sasso et al., 1991; Su et al., 2021); and Protein L (PpL) produced by *Finegoldia magna* (previously known as *Peptostreptococcus magnus*) which binds to the variable light kappa κ (V κ) chain families 1,3,4 (Nilson et al., 1992) at the framework (FWR) 1 region with influence by the other regions (Su et al., 2017).

When bound to the antibodies, these superantigens can reduce the binding of the antibodies to their antigen (Ling et al., 2021), possibly reducing avidity through steric hindrances as in the case of IgM (Samsudin et al., 2020), cause unwanted activation (Su et al., 2021) with downstream effects depending on their isotype (discussed in (Ling et al., 2020a; Gan, 2021)).

With both IgG and V κ as the predominant isotypes in humans (Haraldsson et al., 1991; Janeway et al., 2001), superantigen proteins A, G, and L are likely to underlie significant microbiota-immune axis interactions especially at colonization of mucosal areas. Nonetheless, the problem extends to antibody purification process at which these superantigens are often used. Considering that most therapeutic antibodies are of the IgG and κ isotypes, unwanted interactions of such superantigens produced by commensals at the natural colonization sites can influence the microbiota-immune axis.

Given the widespread implications of these three superantigens, a holistic (Phua et al., 2019; Ling et al., 2020a) and systematic antibody-superantigen investigation using 63 of our previously engineered antibodies (Ling et al., 2018; Lua et al., 2018; Ling et al., 2020b) was performed involving six V κ and seven VH IgGs finding novel interactions for PpL but not for SpA and SpG.

2 Materials and Methods

2.1 Recombinant Antibody Production

All Trastuzumab and Pertuzumab VH and V κ sequences used were described previously (Ling et al., 2018; Ling et al., 2020b). Briefly, the genes were sub-cloned into pTT5 vector (Youbio, Cat: VT2202) using restriction enzyme sites, as previously performed (Su et al., 2017; Ling et al., 2018; Lua et al., 2018; Lua et al., 2019a; Ling et al., 2020b). The plasmids were transformed into competent *E. coli* (DH5 α) strains (Chan et al., 2013) followed by plasmid extraction (Biobasic Pte Ltd, Cat: BS614).

Transfection, production, and purification and were performed as described previously (Ling et al., 2018; Ling et al., 2020b).

2.2 Binding Affinity Quantification

Measurements of superantigen k_a and k_d using the OctetRed® were performed using PpL (Sartorius, Cat: 18-5185), SpA (Sartorius, Cat: 18-5012), and SpG (Sartorius, Cat: 18- 18-5083)

71 biosensor to Pertuzumab and Trastuzumab IgG1 variants in solution. The program and steps used
 72 were as previously described (Su et al., 2017; Ling et al., 2018; Lua et al., 2018; Su et al., 2018; Lua et
 73 al., 2019b; Ling et al., 2020b; Su et al., 2021).

74

75

76 **3 Results**

77 **3.1 Bio-Layer Interferometry (BLI) measurement of recombinant IgG1 variants to Protein A** 78 **(SpA)**

Pertuzumab variants binding Protein A				Trastuzumab variants binding Protein A			
Variable Pairings	KD (M, 10 ⁻⁹)	ka (1/Ms, 10 ⁴)	kd (1/s, 10 ⁻⁴)	Variable Pairings	KD (M, 10 ⁻⁹)	ka (1/Ms, 10 ⁴)	kd (1/s, 10 ⁻⁴)
κ1-H1	1.58	37.79	5.92	κ1-H1	Not Produced		
κ1-H2	1.58	41.43	6.56	κ1-H2			
κ1-H3	0.64	53.29	3.26	κ1-H3			
κ1-H4	1.56	38.64	6.01	κ1-H4			
κ1-H5	Not Produced			κ1-H5	1.06	29.07	3.07
κ1-H6				κ1-H6	Not Produced		
κ1-H7	1.17	42.74	5.02	κ1-H7	0.66	44.31	2.93
κ2-H1	1.90	33.08	6.32	κ2-H1	1.49	17.97	2.68
κ2-H2	1.82	35.57	6.47	κ2-H2	1.46	17.32	2.14
κ2-H3	0.76	55.68	4.23	κ2-H3	0.24	45.66	1.08
κ2-H4	1.57	36.21	5.68	κ2-H4	1.29	35.58	4.51
κ2-H5	1.62	35.83	5.82	κ2-H5	1.11	60.04	6.64
κ2-H6	1.55	38.00	5.91	κ2-H6	1.79	25.36	4.51
κ2-H7	1.15	47.37	5.44	κ2-H7	0.53	57.16	3.04
κ3-H1	1.06	37.25	3.92	κ3-H1	0.25	45.00	1.08
κ3-H2	1.57	40.11	6.30	κ3-H2	1.67	32.31	5.36
κ3-H3	0.69	58.94	4.07	κ3-H3	1.12	20.69	2.31
κ3-H4	1.50	36.19	5.45	κ3-H4	2.30	23.37	5.33
κ3-H5	1.57	39.18	6.18	κ3-H5	0.53	64.07	3.25
κ3-H6	1.43	42.28	6.04	κ3-H6	0.25	45.00	1.08
κ3-H7	1.12	44.12	4.93	κ3-H7	1.67	32.31	5.36
κ4-H1	1.70	37.79	6.43	κ4-H1	1.95	18.22	3.55
κ4-H2	1.46	39.39	5.77	κ4-H2	Not Produced		
κ4-H3	0.58	43.12	2.46	κ4-H3	0.25	45.00	1.08
κ4-H4	1.61	36.02	5.73	κ4-H4	1.67	32.31	5.36
κ4-H5	1.88	34.13	6.40	κ4-H5	1.12	20.69	2.31
κ4-H6	1.85	31.10	5.76	κ4-H6	2.30	23.37	5.33
κ4-H7	1.33	36.54	4.85	κ4-H7	0.53	64.07	3.25
κ5-H1	Not Produced			κ5-H1	Not Produced		
κ5-H2				κ5-H2			
κ5-H3	0.94	18.65	1.74	κ5-H3	0.72	24.60	1.74
κ5-H4	Not Produced			κ5-H4	Not Produced		
κ5-H5				κ5-H5			
κ5-H6				κ5-H6			
κ5-H7				κ5-H7			
κ6-H1	0.94	33.10	3.29	κ6-H1	0.57	27.22	1.52
κ6-H2	0.79	36.64	2.93	κ6-H2	Not Produced		
κ6-H3	0.41	47.42	2.12	κ6-H3	0.31	42.43	1.31
κ6-H4	0.81	36.58	2.64	κ6-H4	1.80	21.44	3.86
κ6-H5	1.26	46.77	5.85	κ6-H5	0.84	83.03	6.97
κ6-H6	Not Produced			κ6-H6	1.78	34.99	6.15
κ6-H7	0.98	49.74	4.85	κ6-H7	0.60	50.44	2.98

Figure 1. BLI measurements (KD, ka and kd) of Pertuzumab and Trastuzumab Vκ1-6 and VH1-7 permutation binding to immobilized SpA biosensor. “Not Produced” denotes that there was insufficient antibody production for the variant despite numerous large-scale transfections. All readings were obtained from at least three antibody concentrations. The readings were the average of independent triplicates.

To examine the potential holistic effect of Vκ1-6 pairing with VH1-7 on antibody interactions with SpA, recombinant Pertuzumab and Trastuzumab IgG1 variants of the various pairings were studied. It should be noted that SpA is known to bind to the CH2 and CH3 of the heavy chain constant (CH).

From Figure 1, the Pertuzumab and Trastuzumab IgG1 variants showed measurements bound to SpA with the equilibrium dissociation constant (KD) at $0.41 - 1.90 \times 10^{-9}$ M and $0.25 - 2.30 \times 10^{-9}$ M, respectively.

For both Pertuzumab and Trastuzumab variants binding to SpA, VH3 was noticed to have a slightly lower, albeit insignificant KD difference at the average of $\sim 0.57 \times 10^{-9}$ M and $\sim 0.53 \times 10^{-9}$ M, respectively, when compared to the other VH families paired with the same Vκ family. This phenomenon is attributed to the higher k_a and lower k_d for the VH3 variant.

3.2 Bio-Layer Interferometry (BLI) measurement of recombinant IgG1 variants to Protein G (SpG)

Pertuzumab variants binding Protein G				Trastuzumab variants binding Protein G			
Variable Pairings	KD (M, 10 ⁻⁹)	ka (1/Ms, 10 ⁴)	kd (1/s, 10 ⁻⁴)	Variable Pairings	KD (M, 10 ⁻⁹)	ka (1/Ms, 10 ⁴)	kd (1/s, 10 ⁻⁴)
κ1-H1	0.28	33.22	0.92	κ1-H1	Not Produced		
κ1-H2	0.31	32.59	1.02	κ1-H2			
κ1-H3	0.87	30.74	2.22	κ1-H3			
κ1-H4	0.30	35.54	1.04	κ1-H4			
κ1-H5	Not Produced			κ1-H5	0.29	32.31	0.91
κ1-H6				κ1-H6	Not Produced		
κ1-H7	0.38	29.75	1.12	κ1-H7	0.39	30.19	1.16
κ2-H1	0.33	29.12	0.96	κ2-H1	0.39	25.84	1.00
κ2-H2	0.36	29.18	1.05	κ2-H2	0.69	22.85	1.57
κ2-H3	0.38	31.21	1.16	κ2-H3	0.29	34.26	0.98
κ2-H4	0.25	34.56	0.83	κ2-H4	0.28	43.48	1.15
κ2-H5	0.30	28.66	0.86	κ2-H5	0.27	37.63	0.97
κ2-H6	0.32	30.00	0.95	κ2-H6	0.33	25.29	0.84
κ2-H7	0.36	30.31	1.06	κ2-H7	0.23	33.30	0.77
κ3-H1	0.27	35.41	0.90	κ3-H1	0.31	30.26	0.92
κ3-H2	0.32	31.47	0.98	κ3-H2	0.48	32.91	1.55
κ3-H3	0.30	31.52	0.94	κ3-H3	0.24	31.94	0.78
κ3-H4	0.24	35.67	0.86	κ3-H4	0.36	26.85	0.97
κ3-H5	0.23	30.77	0.72	κ3-H5	0.23	35.48	0.81
κ3-H6	0.32	30.40	0.95	κ3-H6	0.44	32.45	1.42
κ3-H7	0.27	29.36	0.78	κ3-H7	0.29	29.15	0.86
κ4-H1	0.25	30.68	0.76	κ4-H1	0.36	25.16	0.89
κ4-H2	0.25	32.17	0.78	κ4-H2	Not Produced		
κ4-H3	0.25	30.90	0.75	κ4-H3	0.23	33.18	0.75
κ4-H4	0.25	34.25	0.79	κ4-H4	0.25	35.90	0.89
κ4-H5	0.32	26.48	0.83	κ4-H5	0.22	34.78	0.76
κ4-H6	0.27	27.33	0.75	κ4-H6	0.38	23.19	0.87
κ4-H7	0.28	28.25	0.81	κ4-H7	0.23	37.89	0.82
κ5-H1	Not Produced			κ5-H1	Not Produced		
κ5-H2				κ5-H2			
κ5-H3	0.34	28.58	0.93	κ5-H3	0.32	26.71	0.84
κ5-H4	Not Produced			κ5-H4	Not Produced		
κ5-H5				κ5-H5			
κ5-H6				κ5-H6			
κ5-H7				κ5-H7			
κ6-H1	0.29	30.14	0.87	κ6-H1	0.32	28.24	0.89
κ6-H2	0.31	31.57	0.93	κ6-H2	Not Produced		
κ6-H3	0.28	36.72	1.00	κ6-H3	0.27	30.80	0.86
κ6-H4	0.27	37.20	0.95	κ6-H4	0.36	26.91	0.97
κ6-H5	0.26	33.74	0.81	κ6-H5	0.22	41.89	0.90
κ6-H6	Not Produced			κ6-H6	1.78	34.99	0.51
κ6-H7	0.28	33.32	0.89	κ6-H7	0.30	31.67	0.93

99

100 Figure 2. BLI measurements (KD, ka and kd) of Pertuzumab and Trastuzumab Vκ1-6 and VH1-7
101 permutation binding to immobilized SpG biosensor. “Not Produced” denotes that there was
102 insufficient antibody production for the variants despite numerous large-scale transfections. All
103 readings were obtained from at least three antibody concentrations. The readings were the average of
104 independent triplicates.

105 Testing the 63 recombinant Pertuzumab and Trastuzumab IgG1 variants with SpG which binds
 106 to CH2 and CH3 region, we found high consistency of the interactions between the two Pertuzumab
 107 and Trastuzumab IgG1 variants. Apart from showing similar KDs to the SpA, albeit with narrower
 108 KD ranges of $0.23 - 0.87 \times 10^{-9}$ M and $0.23 - 1.78 \times 10^{-9}$ M, respectively. There is a trend of
 109 Pertuzumab variants binding SpG better than the Trastuzumab counterparts. This slight difference,
 110 while unlikely significant, hints of CDR effects given that the variants differed only at a few residues
 111 in the CDRs.

112

113 **3.3 Bio-Layer Interferometry (BLI) measurement of recombinant IgG1 variants binding to** 114 **Protein L (PpL)**

Pertuzumab variants binding Protein L				Trastuzumab variants binding Protein L			
Variable Pairings	KD (M, 10 ⁻⁹)	ka (1/Ms, 10 ⁴)	kd (1/s, 10 ⁻⁴)	Variable Pairings	KD (M, 10 ⁻⁹)	ka (1/Ms, 10 ⁴)	kd (1/s, 10 ⁻⁴)
κ1-H1	0.76	15.40	1.15	κ1-H1	Not Produced		
κ1-H2	0.68	13.90	0.93	κ1-H2			
κ1-H3	0.53	18.09	0.84	κ1-H3			
κ1-H4	0.57	15.23	0.83	κ1-H4			
κ1-H5	Not Produced			κ1-H5	0.11	15.71	0.17
κ1-H6				κ1-H6	Not Produced		
κ1-H7	0.68	16.05	1.08	κ1-H7	0.14	11.02	0.16
κ2-H1*	148.67	6.36	90.8	κ2-H1	124.41	0.84	9.49
κ2-H2+	15.77	1.68	2.03	κ2-H2+	78.63	2.29	7.71
κ2-H3+	19.91	0.57	0.84	κ2-H3	Poor Response		
κ2-H4	14.4	0.36	0.3	κ2-H4			
κ2-H5	0.93	8.72	0.81	κ2-H5			
κ2-H6	0.72	8.19	0.59	κ2-H6+	190.4	0.24	3.53
κ2-H7*	46.4	2.19	9.66	κ2-H7+	9.79	1.51	0.78
κ3-H1	38.03	91.86	86.08	κ3-H1	17.77	11.68	20.54
κ3-H2	25.42	52.09	127.73	κ3-H2	3.67	7.63	2.58
κ3-H3	29.02	48.16	132.1	κ3-H3	4.34	51.2	21.33
κ3-H4	5.55	53.95	6.99	κ3-H4	5.5	29.5	15.52
κ3-H5	16.85	72.65	70.21	κ3-H5	4.54	49.16	22.25
κ3-H6	23.21	50.68	85	κ3-H6	9.04	15.37	13.53
κ3-H7	17.66	59.87	74.33	κ3-H7	5.08	46.18	23.36
κ4-H1	74.56	18.23	123	κ4-H1	14.18	9.15	12.78
κ4-H2	37.05	24.79	87.04	κ4-H2	Not Produced		
κ4-H3	13.09	22.76	19.45	κ4-H3	9.54	17.19	16.06
κ4-H4	13.66	26.24	20.37	κ4-H4	11.57	16.95	19.57
κ4-H5	54.38	12	64.34	κ4-H5	7.22	20.05	14.4
κ4-H6	23.49	31.68	47.04	κ4-H6	13.03	14.32	18.55
κ4-H7	34.95	20.99	65.46	κ4-H7	10.31	20.34	19.79
κ5-H1	Not Produced			κ5-H1	Not Produced		
κ5-H2				κ5-H2			
κ5-H3	13.58	10.69	13.93	κ5-H3	1.75	10.8	1.85
κ5-H4	Not Produced			κ5-H4	Not Produced		
κ5-H5				κ5-H5			
κ5-H6				κ5-H6			
κ5-H7	13.88	18.87	23.5	κ5-H7			
κ6-H1	Poor Response			κ6-H1+	14.93	5.14	7.53
κ6-H2				κ6-H2	Not Produced		
κ6-H3				κ6-H3*	29.62	6.07	10.81
κ6-H4*	43.46	3.81	10.43	κ6-H4*	74.9	1.65	8.96
κ6-H5+	15.79	1.77	2.8	κ6-H5*	14.84	16.49	11.17
κ6-H6	Not Produced			κ6-H6*	82.16	1.28	8.36
κ6-H7	40.69	0.31	0.8	κ6-H7	60.37	1.77	9.83

Figure 3. BLI measurements (KD, ka and kd) of Pertuzumab and Trastuzumab Vκ1-6 and VH1-7 permutation binding to immobilized SpG biosensor. “Not Produced” denotes that there was insufficient antibody production for the variants despite numerous large-scale transfections. “Poor response” indicates that the particular IgG1 pairing was unable to give response rates within the detection limit across all concentrations. * denotes readings that were derived from two IgG1

concentrations. + denotes represent readings generated derived from only one IgG1 concentration. All other readings were obtained from at least three concentrations. The readings were the average of independent triplicates.

From the total 63 permutations IgG1 variants consisting of 34 Pertuzumab and 29 Trastuzumab permutations of the grafted V κ 1-6 and VH1-7 on PpL, our systematic and holistic investigation of IgG1s to PpL showed non-canonical results of interactions with other V κ families and a contributory role of VH-FWR and complementarity-determining regions (CDRs) to the interaction.

As a control for expected superantigen interactions, the Pertuzumab IgG1s of V κ 1, 3 and 4 interacted with PpL with V κ 1 showing the lowest KD range ($0.53 - 0.76 \times 10^{-9}$ M) followed by V κ 3 ($5.55 - 38.03 \times 10^{-9}$ M) and V κ 4 ($13.09 - 74.56 \times 10^{-9}$ M). The V κ 1 findings were consistent with previous literature (Åkerström and Björck, 1989;Rodrigo et al., 2015;Su et al., 2017). The lower equilibrium dissociation constants (KDs) of the V κ 3 and 4 were due to the lower dissociation rates (kd) despite the higher association rates (ka) than V κ 1. This trend was also observed for the Trastuzumab IgG1s with its V κ 1 showing the lowest KD range ($0.11 \text{ \& } 0.14 \times 10^{-9}$ M) followed by V κ 3 ($3.67 - 17.77 \times 10^{-9}$ M) and 4 ($7.22 - 14.18 \times 10^{-9}$ M). It should be noted that Trastuzumab IgG1s showed lower and a narrower KD range than the Pertuzumab V κ -VH equivalents suggesting effects from the CDRs which were what differed between the two sets of IgG1s.

Interestingly, certain Pertuzumab VHs paired with V κ 2, 5 and 6 exhibited interactions with PpL. Amongst these V κ families, Pertuzumab variants V κ 5 ($13.58 \text{ \& } 13.88 \times 10^{-9}$ M), 6 ($15.79 - 43.46 \times 10^{-9}$ M) and certain V κ 2 permutations (VH2-4 and 7, $14.4 - 46.4 \times 10^{-9}$ M) had KDs comparable to V κ 3 and 4 permutations ($5.55 - 74.56 \times 10^{-9}$ M). PertuzumabV κ 2 paired with VH5 and 6 ($0.93 \text{ \& } 0.72 \times 10^{-9}$ M, respectively) had KDs comparable to V κ 1 ($0.53 - 0.76 \times 10^{-9}$ M) while V κ 2 paired with VH1 had the highest KD (poorest binding) of 148.67×10^{-9} M. There were also non-binding IgG1s of the Pertuzumab V κ 6 permutation with VH1-3 (Poor Response) despite measurable responses when paired with VH4, 5 and 7.

Interesting, the Pertuzumab trends were largely repeated in the Trastuzumab IgG1s where KDs of V κ 5 (1.75×10^{-9} M) and 6 ($14.84 - 82.16 \times 10^{-9}$ M) and V κ 2 paired with VH2 & 7 ($78.63 \text{ \& } 9.79 \times 10^{-9}$ M, respectively) had KD values comparable to V κ 3 and 4 ($3.67 - 14.18 \times 10^{-9}$ M). Trastuzumab V κ 2 paired with VH1 & 6 had the highest KD (poorest interaction) at $124.41 \text{ \& } 190.4 \times 10^{-9}$ M, respectively. The non-binders were Trastuzumab V κ 2 paired with VH3 – 5 (Poor Response) rather than in V κ 6 family observed for Pertuzumab. These differences demonstrated a role of the CDRs and a significant contributory role of VH in PpL engagement.

4 Discussion

We set out to investigate the interactions of superantigens Protein A, G and L systematically and holistically with the various regions of IgG1 antibodies. By using CDRs of Pertuzumab and Trastuzumab grafted onto V κ 1-6 and VH1-7 FWRs and pairing them within the two antibody models, measurements to the antibody superantigens showed no major differences for SpA between Pertuzumab and Trastuzumab IgG1 variants (Figure 1). This was expected given that SpA bound IgG1s predominantly at the CH2-CH3 regions (Deisenhofer, 1981) with some contributions from the VH3 framework (Su et al., 2021) that is also observed here to a lesser extent where the V κ chains paired with VH3 showed a slightly lower KD measurement compared to the rest of the variants. Yet,

this difference is notably less pronounced compared to our previous work on IgEs (Su et al., 2021) with the same V_κs-VH where the VH3-CDR2 S58 residue had a more significant role in SpA binding for IgEs.

With respect to SpG interaction, no notable differences in KDs (Figure 2) were observed among the 63 IgG1 variants. As was with SpA, which shared an overlapping binding site on the CH2-CH3 region of IgGs (Kato et al., 1995), there was in fact a narrower range that we attributed to the lack of interference from the V-regions present for SpA. While SpG was previously reported (Choe et al., 2016) to bind to IgG1 better than SpA, this trend was more pronounced in our study.

Measurements of PpL interactions to Pertuzumab and Trastuzumab variants expectedly showed that VHs paired with V_κ1, 3 and 4 to have KDs as per previously reported (Nilson et al., 1992; Su et al., 2017). Surprisingly, we found non-canonical interaction of PpL with V_κ2 that were previously determined to not bind PpL (Nilson et al., 1992) while there is no report of V_κ5 & 6 at the time of writing. In our own work involving light chain productions alone, we also affirmed that these secreted V_κ2, 5 and 6 light chain dimers did not interact with PpL on the same BLI experiments (Supplementary Figure 1). Notable binders to PpL are: Pertuzumab V_κ2 – VH1-7; V_κ5 – VH3 & 7; V_κ6 – VH4, 5 & 6; Trastuzumab V_κ2 – VH1, 2, 5 & 6; V_κ5 – VH3; V_κ6 – VH1, 3-7 (Figure 3).

Although the novel V_κ IgG1s bound PpL showed comparable KDs, it should be noted that the KDs were calculated from one (+ in Figure 3) or two (* in Figure 3) antibody concentrations, generally from the highest concentrations (100 nM and below) of the Ig variant. The notable exceptions were that of Pertuzumab V_κ2 – VH4-6, V_κ5 – VH3 & 7, V_κ6 – VH6, Trastuzumab V_κ2 – VH1, V_κ5 – VH3, V_κ6 – VH7 with KDs calculated from at least three concentrations. Interestingly, two variants: Pertuzumab V_κ2 – VH5 & 6 showed KDs comparable to V_κ1 – VHs values.

The unexpected IgG1 variants interacting with PpL suggested a combined VH-V_κ induced binding site to PpL that may be similar to the non-canonical binding of IgEs to Nickel (Su et al., 2021) in our previous work using the same V-regions. In fact, the IgG1s were validated with the expected interactions to SpA and SpG here, and also with the Fcγ2A and Her2 in our previous work (Ling et al., 2018). Given the lack of interactions between V_κ 2, 5 and 6 with PpL, and the lack of consistency between the Trastuzumab and Pertuzumab variants where for Pertuzumab, the non-binders exist for Pertuzumab V_κ6 – VH1-3 and Trastuzumab V_κ2 – VH3-5 (labelled as “Poor Response” pairs in Figure 3), the PpL interaction is certainly beyond V-region pairings alone.

With the differences between the Pertuzumab and Trastuzumab which share very similar V-regions, our findings further demonstrate the need for a design thinking (Ling et al., 2020a) approach involving holistic antibody investigations approach (Phua et al., 2019). Such an approach allowed detailed investigations for unexpected interactions between the antibodies with other proteins that can have notable immune effects, as was with our unexpected findings of IgAs binding to SpG (Ling et al., 2021). With relevance to the development of therapeutics where a personalized antibody approach may be beneficial to avoid unwanted side effects, such interactions may also be engineered in for purification purposes.

5 Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

206

207 **6 Author Contributions**

208 Conceptualization, W.L.L. and S.K-E.G.

209 Methodology, W.L.L. and S.K-E.G.

210 Investigation, W.L.L. and S.K-E.G

211 Validation, J.Y.Y.

212 Writing – Original Draft, W.L.L. and S.K-E.G

213 Writing – Review & Editing, W.L.L., Y.L.N. and S.K-E.G

214 Funding Acquisition, S.K-E.G.

215 Supervision, S.K-E.G., Y.L.N. and A.W.

216

217 **7 Funding**

218 This work was partially supported by the Joint Council Office, Agency for Science,
219 Technology, and Research, Singapore under Grant number JCO1334i00050 and the National
220 Research Foundation (NRF) Singapore grant to Experimental Drug Development Centre (EDDC).

221

222 **8 Acknowledgments**

223 This is a short text to acknowledge the contributions of specific colleagues, institutions, or
224 agencies that aided the efforts of the authors.

225

226 **9 References**

227 Åkerström, B., and Björck, L. (1989). Protein L: An Immunoglobulin Light Chain-binding Bacterial
228 Protein: Characterization of binding and physicochemical properties *. *Journal of Biological*
229 *Chemistry* 264, 19740-19746.

230 Chan, W.-T., Verma, Chandra s., Lane, David p., and Gan, Samuel k.-E. (2013). A comparison and
231 optimization of methods and factors affecting the transformation of Escherichia coli.
232 *Bioscience Reports* 33.

233 Choe, W., Durgannavar, T.A., and Chung, S.J. (2016). Fc-Binding Ligands of Immunoglobulin G:
234 An Overview of High Affinity Proteins and Peptides. *Materials (Basel, Switzerland)* 9, 994.

235 Deacy, A.M., Gan, S.K.-E., and Derrick, J.P. (2021). Superantigen Recognition and Interactions:
236 Functions, Mechanisms and Applications. *Frontiers in Immunology* 12.

237 Deisenhofer, J. (1981). Crystallographic refinement and atomic models of a human Fc fragment and
238 its complex with fragment B of protein A from *Staphylococcus aureus* at 2.9- and 2.8-Å resolution.
239 *Biochemistry* 20, 2361-2370.

240 Gan, S.K.P., S.; Yeo, J.Y. (2021). Sagacious Epitope Selection for Vaccines, and Both Antibody-
241 Based Therapeutics and Diagnostics: Tips From Virology and Oncology. *Preprints*.

242 Grov, A., Myklestad, B., and Oeding, P. (1964). IMMUNOCHEMICAL STUDIES ON ANTIGEN
243 PREPARATIONS FROM *STAPHYLOCOCCUS AUREUS*. *Acta Pathologica*
244 *Microbiologica Scandinavica* 61, 588-596.

245 Haraldsson, Á., Kock-Jansen, M.J.H., Jaminon, M., V Eck-Arts, P.B.J.M., De Boo, T., Weemaes,
246 C.M.R., and Bakkeren, J.a.J.M. (1991). Determination of Kappa and Lambda Light Chains in
247 Serum Immunoglobulins G, A and M. *Annals of Clinical Biochemistry* 28, 461-466.

248 Janeway, C.A., Travers, P., Walport, M., and Capra, D.J. (2001). *Immunobiology*. Taylor & Francis
249 Group UK: Garland Science.

250 Kato, K., Lian, L.-Y., Barsukov, I.L., Derrick, J.P., Kim, H., Tanaka, R., Yoshino, A., Shiraishi, M.,
251 Shimada, I., Arata, Y., and Roberts, G.C.K. (1995). Model for the complex between protein G
252 and an antibody Fc fragment in solution. *Structure* 3, 79-85.

253 Ling, W.-L., Lua, W.-H., and Gan, S.K.-E. (2020a). Sagacity in antibody humanization for
254 therapeutics, diagnostics and research purposes: considerations of antibody elements and their
255 roles. *Antibody Therapeutics* 3, 71-79.

256 Ling, W.-L., Lua, W.-H., Poh, J.-J., Yeo, J.Y., Lane, D.P., and Gan, S.K.-E. (2018). Effect of VH-
257 VL Families in Pertuzumab and Trastuzumab Recombinant Production, Her2 and FcγIIA
258 Binding. *Frontiers in Immunology* 9.

259 Ling, W.-L., Su, C.T.-T., Lua, W.-H., Poh, J.-J., Ng, Y.-L., Wipat, A., and Gan, S.K.-E. (2020b).
260 Essentially Leading Antibody Production: An Investigation of Amino Acids, Myeloma, and
261 Natural V-Region Signal Peptides in Producing Pertuzumab and Trastuzumab Variants.
262 *Frontiers in Immunology* 11.

263 Ling, W.-L., Su, C.T.-T., Lua, W.-H., Yeo, J.Y., Poh, J.-J., Ng, Y.-L., Wipat, A., and Gan, S.K.-E.
264 (2021). Engaging the 'A' Class Antibody: Variable-Heavy (VH) region influencing
265 IgA1 engagement of FcαRI and superantigen proteins G, A, and L. *bioRxiv*,
266 2021.2009.2027.461897.

267 Lua, W.-H., Ling, W.-L., Yeo, J.Y., Poh, J.-J., Lane, D.P., and Gan, S.K.-E. (2018). The effects of
268 Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models:
269 Impact on antibody production and antigen-binding. *Scientific Reports* 8, 718.

270 Lua, W.-H., Su, C.T.-T., Yeo, J.Y., Poh, J.-J., Ling, W.-L., Phua, S.-X., and Gan, S.K.-E. (2019a).
271 Role of the IgE variable heavy chain in FcεRIα and superantigen binding in
272 allergy and immunotherapy. *Journal of Allergy and Clinical Immunology* 144, 514-523.e515.

273 Lua, W.-H., Su, C.T.-T., Yeo, J.Y., Poh, J.-J., Ling, W.-L., Phua, S.-X., and Gan, S.K.-E. (2019b).
274 Role of the IgE variable heavy chain in FcεRIα and superantigen binding in allergy and
275 immunotherapy. *Journal of Allergy and Clinical Immunology* 144, 514-523.e515.

276 Nilson, B.H., Solomon, A., Björck, L., and Akerström, B. (1992). Protein L from *Peptostreptococcus*
277 *magnus* binds to the kappa light chain variable domain. *J Biol Chem* 267, 2234-2239.

- Phua, S.-X., Chan, K.-F., Su, Chinh t.-T., Poh, J.-J., and Gan, Samuel k.-E. (2019). Perspective: The promises of a holistic view of proteins—impact on antibody engineering and drug discovery. *Bioscience Reports* 39.
- Rodrigo, G., Gruvegård, M., and Van Alstine, J.M. (2015). Antibody Fragments and Their Purification by Protein L Affinity Chromatography. *Antibodies* 4, 259-277.
- Samsudin, F., Yeo, J.Y., Gan, S.K.-E., and Bond, P.J. (2020). Not all therapeutic antibody isotypes are equal: the case of IgM versus IgG in Pertuzumab and Trastuzumab. *Chemical Science* 11, 2843-2854.
- Sasso, E.H., Silverman, G.J., and Mannik, M. (1991). Human IgA and IgG F(ab')₂ that bind to staphylococcal protein A belong to the VHIII subgroup. *The Journal of Immunology* 147, 1877-1883.
- Sjöbring, U., Björck, L., and Kastern, W. (1991). Streptococcal protein G. Gene structure and protein binding properties. *J Biol Chem* 266, 399-405.
- Spaulding, A.R., Salgado-Pabón, W., Kohler, P.L., Horswill, A.R., Leung, D.Y.M., and Schlievert, P.M. (2013). Staphylococcal and Streptococcal Superantigen Exotoxins. *Clinical Microbiology Reviews* 26, 422-447.
- Su, C.T.-T., Ling, W.-L., Lua, W.-H., Poh, J.-J., and Gan, S.K.-E. (2017). The role of Antibody V κ Framework 3 region towards Antigen binding: Effects on recombinant production and Protein L binding. *Scientific Reports* 7, 3766.
- Su, C.T.-T., Lua, W.-H., Ling, W.-L., and Gan, S.K.-E. (2018). Allosteric Effects between the Antibody Constant and Variable Regions: A Study of IgA Fc Mutations on Antigen Binding. *Antibodies* 7, 20.
- Su, C.T.-T., Lua, W.-H., Poh, J.-J., Ling, W.-L., Yeo, J.Y., and Gan, S.K.-E. (2021). Molecular Insights of Nickel Binding to Therapeutic Antibodies as a Possible New Antibody Superantigen. *Frontiers in Immunology* 12.

303

304 **10 Data Availability Statement**

305 The datasets GENERATED/ANALYZED for this study is available upon request.

306

307 **Figure Legends**

308 Figure 1. BLI measurements (KD, k_a and k_d) of Pertuzumab and Trastuzumab V κ 1-6 and VH1-7
 309 permutation binding to immobilized SpA biosensor. “Not Produced” denotes that there was
 310 insufficient antibody production for the variant despite numerous large-scale transfections. All
 311 readings were obtained from at least three antibody concentrations. The readings were the average of
 312 independent triplicates.

313 Figure 2. BLI measurements (KD, k_a and k_d) of Pertuzumab and Trastuzumab V κ 1-6 and VH1-7
 314 permutation binding to immobilized SpG biosensor. “Not Produced” denotes that there was
 315 insufficient antibody production for the variants despite numerous large-scale transfections. All

316 readings were obtained from at least three antibody concentrations. The readings were the average of
317 independent triplicates.

318 Figure 3. BLI measurements (KD, k_a and k_d) of Pertuzumab and Trastuzumab V κ 1-6 and VH1-7
319 permutation binding to immobilized SpG biosensor. “Not Produced” denotes that there was
320 insufficient antibody production for the variants despite numerous large-scale transfections. “Poor
321 response” indicates that the particular IgG1 pairing was unable to give response rates within the
322 detection limit across all concentrations. * denotes readings that were derived from two IgG1
323 concentrations. + denotes represent readings generated derived from only one IgG1 concentration.
324 All other readings were obtained from at least three concentrations. The readings were the average of
325 independent triplicates.